Here are six key notes:
1. The partnership will focus on using nanotechnologies based on Cour’s Tolerizing Immune Modifying nanoParticle platform.
2. The collaboration will explore the potential of TIMP therapy to allow celiac patients to tolerate gluten in their diet.
3. The TIMPs consist of a proprietary polymer and antigenic proteins.
4. Cour will receive upfront and success based milestone payments from Takeda.
5. Cour will also receive royalties on sales of any successful commercialized products resulting from the partnership.
6. Takeda will have the option to collaborate on up to three additional TIMP compounds.
More articles on GI/endoscopy:
A day in the life: 24 statistics on how gastroenterologists spend their time
5 most-read GI/endoscopy stories: Week of Nov. 30 – Dec. 4
FDA clears 5 GI/endoscopy devices in November
